Sunshine Biopharma, Inc. Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a

MONTREAL--(Marketwire - October 09, 2012) - Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has received the Scale-Up Manufacturing Protocol from the Contract Manufacturing Organization (CMO) and is now poised to begin the process of manufacturing gram quantities of Adva-27a in preparation for conducting initial IND-Enabling studies. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR). Initial or Pre-IND-Enabling studies include a variety of in vitro biological tests as well as studies in live rats and mice in order to ascertain that the scale-up manufacturing process generates a compound that is identical to the original used in the pre-clinical studies.

“We are very excited to be at the scale-up stage and have the capacity to manufacture gram quantities of our Adva-27a compound,” said Mr. Camille Sebaaly, Sunshine Biopharma’s CFO. “This is a very important milestone in our Adva-27a development program,” he added.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.